HONG KONG, March 30, 2023 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2022 (the "Reporting Period").
In 2022, the increasingly sophisticated macro environment, the US dollar interest rate hikes, and geopolitical tensions continued to disrupt the economy. Fosun firmly implemented a focused strategy, continued to lay the solid foundation for its development, and achieved steady development in its core businesses. During the Reporting Period, the Group achieved a total revenue of RMB175.39 billion, representing a year-on-year increase of 8.7%. Focusing on the needs of global families in health, happiness, and wealth, the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group (FTG) continued to enhance their products and services, accounting for 72% of the Group's total revenue. Among them, FTG's revenue increased significantly by 49% to RMB13.78 billion. Due to the recurrent outbreak of COVID-19 pandemic in 2022 and the turmoil and downturn of the international capital markets, resulting in high business costs and an increase in floating losses in secondary capital market investment, the Group's overall industry operations and industrial investment have been affected to varying degrees. During the Reporting Period, the net profit attributable to owners of the parent amounted to RMB0.54 billion.
During the Reporting Period, Fosun continued to optimize its capital and asset structure by actively managing its debt to effectively cope with violent fluctuations in the capital market and maintain resilient liquidity. As of the end of the Reporting Period, cash and bank balances and time deposits were abundant, amounting to RMB100.56 billion; the ratio of total debt to total capital was 53.2%, and down 3.6 percentage points compared to mid-2022; the average cost of debt was at a low level of 4.7%; the adjusted NAV was HK$21.6 per share.
It is worth mentioning that in January 2023, the Group entered into a syndicated loan agreement for an amount of RMB12 billion with eight domestic banks, which was the largest private corporate syndicated loan led by five major state-owned banks in cooperation with policy banks and joint-stock banks since the announcement of "encouraging and supporting the development of the private economy and private enterprises" at the Central Economic Working Conference held in December 2022.
In 2022, Fosun's global operations capability was further enhanced, with overseas revenue amounting to RMB77.4 billion, representing a year-on-year increase of 14% and accounting for 44% of the total revenue. As of the end of the Reporting Period, Fosun had 43 overseas brand enterprises and more than 45,000 overseas employees. The Group's R&D investment reached RMB10.4 billion, representing a year-on-year increase of 17%; as of the end of 2022, Fosun had 1,771 patents for inventions.
The synergy capability of Fosun's FC2M global ecosystem was further enhanced, highlighting the multiplier effect of the ecosystem. During the Reporting Period, the Group's ecosystem has created a total value of more than RMB6.9 billion, and has 133 products that generated more than RMB100 million sales for each, and among them 22 were new products; 50.8 million new registered members during the year, representing a year-on-year increase of 27%. Among them, the two top C-end platforms continued to facilitate the rapid and high-quality growth of members. During the Reporting Period, Fosun Health acquired 9.24 million registered users, bringing the cumulative number of registered members to 22.58 million. As of the end of the Reporting Period, Fosun Alliance has accumulated 6.4 million registered members.
Since the beginning of 2023, businesses in consumer and tourism sectors have shown a strong upward trend. In 2023, the Yuyuan Garden Lantern Festival which received wide recognition in Chinese mainland and overseas became the talk of the town and attracted more than 4 million visits, effectively driving consumption in the area. Fosun's tourism business has rebounded rapidly, Atlantis Sanya, a subsidiary of FTG, its business has fully recovered and surpassed the level before the pandemic, recorded a business volume of RMB399 million in the first two months of 2023, representing an increase of 10% compared to the same period of 2022, the average occupancy rate by room reached 96%. The business volume of Club Med and Lijiang FOLIDAY Town increased by 55% and 149% respectively compared to the same period in 2022.
Guo Guangchang, Chairman of Fosun International, said: "Fosun firmly promoted the strategy of focusing on its core businesses, made clear the positioning of "a global innovation-driven consumer group" and the mission of "serving one billion families worldwide". In the future, we will continue to strengthen innovation, deepen global operations, and refine more good products and services. With our endeavors, we hope to create happier lives for families."
View original content:https://www.prnewswire.com/apac/news-releases/fosun-internationals-total-revenue-in-2022-amounted-to-rmb175-39-billion-up-8-7-year-on-year-301785989.html
SOURCE Fosun
BANGKOK, March 30, 2023 /PRNewswire/ -- Sasin School of Management has partnered with SCG Chemicals (SCGC), an innovator of chemical innovations and solutions, to host SCG Bangkok Business Challenge @ Sasin 2023 - Global Competition to fuel the future of entrepreneuship. This competition invites passionate undergraduate and postgraduate students from every country to pitch ideas on sustainable business development that prioritizes environmental, social, and good governance. The winners will receive trophies and cash prizes worth US$42,000.
SCG Bangkok Business Challenge @ Sasin is Asia's longest–running student startup competition that provides university students with an entrepreneurial mindset the opportunity to pitch their innovative business developmental ideas and demonstrate management skills through the visions of their startup. This year's Global Competition theme is "Growing Impactful Ventures" to foster innovative, sustainable, and creative approaches in business management. The competition also aims to inspire all participating teams to tackle future business challenges prioritizing sustainability, social responsibility, and environmental consciousness.
Undergraduate and postgraduate students interested in the competition can submit their applications for the Global Competition from today until April 30, 2023. The semi-final and finals will take place on June 22-24, 2023, at Sasin School of Management in Bangkok, Thailand. Let's join the force for sustainability through an entrepreneurship mindset as all participants compete for the chance to win a trophy, cash prizes, and the opportunity to network with other international teams.
Submit your applications at https://bit.ly/apply2bbcgl2023. For more information on the competition, visit https://bbc.sasin.edu/2023 or Facebook page: bangkokbusinesschallenge
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/sasin-and-scgc-drive-the-startup-ecosystem-through-scg-bangkok-business-challenge--sasin-2023---global-competition-for-university-students-301785978.html
SOURCE Sasin School of Management
- Sealed the deal with Liithos Inc., Hit Factor Inc., and PM Champions LLC at GDC 2023
- Titles including Ashfall, Glimmer Peak and Roshpit Champions 2 to be serviced on WEMIX PLAY
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- Wemade, a South Korean gaming and blockchain giant, signed MOUs for strategic partnerships with three North American game developers Liithos Inc., Hit Factor Inc., and PM Champions LLC.
The companies met at GDC 2023 and agreed to join forces in expanding the WEMIX ecosystem. Ashfall by Liithos and Roshpit Champions 2 by PM Champions will onboard WEMIX PLAY, Wemade's blockchain game platform. Hit Factor will soon disclose details of its onboarding game.
"Today, Liithos and Wemade have entered into a strategic partnership to develop AAA Web 3 games for global audiences", said Michael Mumbauer, CEO of Liithos. "We couldn't be more thrilled to work alongside their blockchain gaming experience and leverage their experience and the WEMIX PLAY game platform for next generation audiences."
"We are honored to announce that we have entered into a strategic partnership with WEMIX," said Cooper Bachman, CEO of Hit Factor. "The team is incredibly excited to create engaging and groundbreaking experiences for our players around the world utilizing WEMIX's cutting-edge blockchain platform."
"I am thrilled to announce our partnership with Wemix, offering their expertise in blockchain technology and an extensive network of industry connections," said Ryan Racioppo, CEO of PM Champions. "Working with WEMIX will ensure the highest possible quality for our game upon release and underscores our commitment to delivering an unforgettable gaming experience for our players."
WEMIX PLAY currently focuses on building a more robust game line-up and genre diversifying for a more competitive edge. Various blockchain games are currently being serviced on the platform, information about which can be found on its official website https://wemixplay.com/ .
Wemade participated in GDC 2023, held from 20th to 24th March, and had meetings with game developers from around the world. Several speeches were also given by its key members to introduce a vision of the blockchain game market and the strength of the global number 1 blockchain game platform WEMIX PLAY.
About WEMADE
"Where Games Change"
WEMADE is a renowned industry leader in game development with over 20 years of experience as well as a pioneer for mass adoption of blockchain technology in the global gaming industry. Through more than two decades of game development and servicing experience, WEMADE genuinely understands what it takes to create good games for the global gaming community.
About the WEMIX "Mega-ecosystem"
WEMIX is a robust EVM-compatible open source protocol powered by SPoA (Stake-based Proof of Authority) consensus algorithm which is secured by 40 decentralized authority nodes operated by highly-qualified global partners as well as on-chain community DAO (Decentralized Autonomous Organization), collectively known as the 40 WONDERS. It is designed to be an experience-based, platform-driven & service-oriented mega-ecosystem home to innovative projects and applications built by the community for the world.
About WEMIX PLAY
"Life is Game"
WEMIX PLAY is the world's largest blockchain gaming platform servicing millions of gamers from around the globe. WEMIX PLAY opens a new door into the future of gaming through its modular transformation that implements Tokenomics, GameFi, Marketplace, and Community to good games. Onboarding WEMIX PLAY is the answer to all your questions. All you need to do as developers is to focus on creating good games.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/wemade-signs-strategic-partnerships-with-three-north-american-game-developers-aims-to-add-three-games-to-its-lineup-301785970.html
SOURCE Wemade Co., Ltd
HONG KONG, March 30, 2023 /PRNewswire/ -- In the year of 2022, Toshiba TV ranked first in the Japanese market share, and third in Egypt for the craftsman's consistent innovation.*
Toshiba TV is set to release a new product fitted with the latest refresh rate panel: the 144Hz native display for premium motion.
The refresh rate panel, which refers to the number of times a television updates motion images per second, directly impacts the smoothness and clarity of what is displayed on the screen, especially fast-moving content such as sports, action movies, and essentially, video games.
Without a doubt, Toshiba TV's upcoming new model, the Z870, inbuilt with the nifty 144Hz refresh rate for optimal display performance was innovated with gamers in mind.
For the complete quality gaming ensemble, these new Toshiba TV models also pack in an impressive Game Mode Pro, promising an all-immersive game time.
The Game Mode Pro is an assortment of gameplay-enhancing sub-features such as the Auto Low Latency Mode (ALLM) for seamless connection of gaming devices to the television; the AMD FreeSync technology for tear-free and stutter-free gaming; and the Variable Refresh Rate (VRR) for dynamic refresh rate synchronization. These features convincingly cater to scene-by-scene needs for real and quick gameplay.
Complementing a solid structure for performance, Toshiba TV pays due attention to pristine display quality with the inclusion of the Mini LED display technology, which allows for precise backlighting, improved local dimming, high color vibrancy, and enhanced energy efficiency. These features are powered by the REGZA chip, Toshiba TV's signature image processor for premium image resolution upconversion, color enhancement, and contrast optimization.
To all who anticipate the launch of the Toshiba TV Z870, the model is expected to be launched soon as July this year. From all indications, this new addition to the Toshiba TV flagship should continue the streaks of success across local and international markets.
*Source: BCN, GFK
About Toshiba TV
Toshiba TV has 71 years of history in TV production. With its strong DNA in inventions and innovative ideas, Toshiba TV has produced many TVs with the world's first features. Toshiba TV has provided unforgettable experiences and new viewing styles to many people around the world through its high image quality.
For more details, stay tuned to Toshiba TV on Facebook, Instagram, Twitter, YouTube.
SOURCE Toshiba TV
DHAKA, Bangladesh, March 30, 2023 /PRNewswire/ -- Huawei and bKash agreed to deepen partnership in Bangladesh, to further drive financial inclusion and enable more people to participate in and benefit from digital economy in the country. bKash, Bangladesh's largest mobile payment operator, provides mobile financial services to 68 million people, caters to every family in Bangladesh. Huawei powers bKash's services with its cutting-edge digital finance solutions.
To take the journey forward, Pan Junfeng, President, Huawei South Asia Region & CEO, Huawei Bangladesh and Kamal Quadir, Founder and CEO of bKash have signed an MoU at Huawei Bangladesh Academy on Wednesday, 29thMarch 2023 in Dhaka.
Speaking at the MoU signing ceremony titled "Smart Fintech: Inclusive. Innovative. Inspiring Bangladesh", Kamal Quadir, Founder and CEO of bKash highlighted the significance of the partnership.
"Financial inclusion and inclusive services have been part of bKash's DNA since its inception in 2011. At the advent of the fourth industrial revolution, we are working tirelessly towards a digital financial ecosystem and becoming a Smart Nation. The joint effort of bKash and Huawei aims at driving financial inclusion and eliminating poverty for SDGs with innovative solutions," said Kamal.
Since development of the current FinTech products, Huawei has deployed its platform across more than 30 markets in Asia and Africa. In total, Huawei's FinTech solutions are being used by over 400 million people worldwide.
Pan Junfeng, President, Huawei South Asia Region & CEO, Huawei Bangladesh said that the strengthened partnership between Huawei and bKash in Bangladesh aims to drive digital inclusion in the country.
"Since 2017, Huawei has been working closely with bKash in digitalizing its MFS with the leading Mobile Money platform. The platform offers services such as e-wallet and Nano-loan, bringing financial inclusion and innovation to local communities. Moving forward, we will continue to deepen our partnership to empower and enable more people in Bangladesh to seize the benefits of the digital economy for development. And I believe that our partnership will drive the growth of the digital economy in Bangladesh, setting a remarkable example to other EM countries in the region, when it comes to financial inclusion," said Pan.
Speaking at the event Sarder M Asaduzzaman, Assistant Resident Representative of the United Nations Development Programme highlighted the contribution of MFS in the development and in achieving the target of SDGs, "This initiative: smart fintech bringing an inclusive, innovative, and inspiring Bangladesh carries heavy weight and insights. I believe both Huawei and bKash agree and are working on that. And their further partnership will reinforce the whole initiative."
"SDG is the end goal, it is where we want to be in the 2030s. We are on the path and this Smart Fintech partnership is the vehicle that will drive us to get there." said Ms. Susan Vize, Officer-in-Charge of the United Nations Educational, Scientific and Cultural Organization (UNESCO) Dhaka Office.
SOURCE Huawei
HUNTSVILLE, Ala., March 30, 2023 /PRNewswire/ -- Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, has announced that Discovery Genomics is the first commercial service laboratory in the world to receive two of the new NovaSeq™ X Plus Sequencing Systems from Illumina, Inc. Discovery Genomics will expand its platform to five systems by the end of the year―positioning itself as the commercial laboratory with the world's largest NovaSeq X Plus commercial fleet.
The NovaSeq X Plus is a game-changer in the field of genomics, boasting three flow cell types and generating up to 16 Tb of output per run with dual flow cells. Its ultra-high-density flow cells and ultra-high-resolution optics enable output of up to 26 billion single reads per flow cell. The system can simultaneously perform up to four applications per flow cell, with integrated secondary analysis capabilities, making it a uniquely powerful and versatile tool for genomics research.
"We are thrilled to be the first commercial service laboratory in the world to receive two of the new NovaSeq X Plus systems," said Tom Halsey, Ph.D., executive vice president of Discovery Genomics. "With the expansion of our fleet to five systems, we are uniquely positioned to provide the highest capacity to generate genomic data more cost effectively, furthering our mission to enable our clients' success by delivering world-class genomic services with speed, scale, and quality."
Discovery Genomics' scientists are immediately launching the bridging studies necessary to validate workflows from existing sequencers to the NovaSeq X Plus, which will expedite the transfer of client projects to the more efficient and cost-effective platform. The X Plus, combined with individually addressable flow cell lanes, flexible run options, and simplicity of operation, will enable Discovery Genomics to deliver the market-leading scale and speed to provide the highest quality results at substantially reduced costs and timelines.
"Cross-validation of our existing WGS, WES, RNA-Seq libraries for both standard and low input workflows on the newly installed Illumina NovaSeq X Plus instruments has already begun," said Nripesh Prasad, Ph.D., vice president of scientific and technical development for Discovery Genomics. "This cross-validation data will help us quickly bridge the NovaSeq 6000 and X-Plus chemistries so customers can confidently utilize the new technology for their high-throughput projects at unprecedented speed and scale while reducing their overall project costs."
Discovery's CLIA-certified, CAP-accredited, and GCLP-compliant Genomics Laboratory offers a wide range of scalable next-generation sequencing (NGS) services, including RNA, whole exome, whole genome, targeted, single cell, and epigenetic sequencing. Its proprietary comprehensive genomic profiling workflow enables interrogation of most difficult sample types, such as formalin-fixed paraffin-embedded (FFPE) and core needle biopsies (CNB) samples.
Discovery Life Sciences will be relocating to a new 100,000 sq ft. world headquarters this summer, offering one of the largest installments of the leading edge multi-omic biomarker technologies, including the Illumina NovaSeq X Plus Systems, under one roof. The facility will house genomics, proteomics, molecular pathology, and flow cytometry laboratories. A fully integrated LIMS system will track the chain of custody of a research or clinical trial sample from receipt through multiple technologies, producing comprehensive and actionable data in the shortest possible time.
About Discovery Life Sciences
Discovery Life Sciences is the company of Biospecimen and Biomarker Specialists, combining one of the world's largest commercial biospecimen inventory and procurement networks with preeminent multi-omic biomarker service laboratories, including genomic, tissue biomarker, proteomic, and flow cytometry services to accelerate new therapies supported by biomarker and companion diagnostic programs for cancer, infectious disease, and other rare and complex conditions.
Through AllCells®, our cell and gene therapy division, we maintain the largest recallable donor pool to supply Research Use Only (RUO) and clinical-grade fresh and cryopreserved human cellular materials to support cell and gene therapy programs in any phase of development and at any scale.
Discovery's leading scientific expertise, scale of global operations, and innovative use of current technologies allow customers to obtain results to make critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com.
View original content:SOURCE Discovery Life Sciences
NINGBO, China, March 30, 2023 /PRNewswire/ -- TUV Rheinland Greater China, an international independent third-party testing, inspection and certification organization, held a strategic cooperation signing ceremony with smart Automobile. The two companies will start in-depth cooperation in the fields of green, low-carbon, and sustainability, giving full play to their respective technical and resource advantages to promote the low-carbon transformation and sustainable development of the global automotive value chain. Michael Weppler, Executive Vice President of Sales, Marketing and Communications at TUV Rheinland, and Yang Jun, Vice President of Research and Development at smart Automobile, signed a memorandum of cooperation on behalf of both sides. Other attendees included Li Tao, Vice President of TUV Rheinland Greater China Strategy, Marketing and Business Development, Fallight Xu, General Manager of TUV Rheinland Greater China Sustainability Service, and Dr. Du Hanbin, Chief Engineer of Research and Development at smart Automobile.
In the context of global carbon neutrality, electric vehicles are given high hopes in the low-carbon transformation of society. The carbon footprint of the power battery, one of the key components, as well as the low carbonization of the whole supply chain, determines the extent to which electric vehicles can contribute to the green economy.
According to the agreement, TUV Rheinland will work with smart to develop environment-friendly evaluation standards, methods, and practices for product life cycle evaluation and carbon footprint calculation, product classification rules and carbon emission data sets for automotive vehicles and components such as power batteries, and evaluation standards for green and zero-carbon manufacturing in the automotive industry, as well as an evaluation index scheme for a green and sustainable supply chain according to the current status of production and operation in the automotive industry.
At the signing ceremony, Michael Weppler stated that last September the smart #1 power battery was awarded China's First Carbon Footprint Certificate based on the EU Product Environmental Footprint Category Rules (PEFCR) & ISO 14067 by TUV Rheinland, setting a solid example for low carbon and emission reduction in the field of electric vehicles. The signing of this agreement is an important milestone in the cooperation between the two sides. TUV Rheinland will make full use of its technical capability over more than 100 years in the field of automotive testing and certification and its rich experience in the field of low-carbon energy and sustainability. Combined with smart's technical resources in the field of automotive vehicles and power batteries, the two sides will jointly develop relevant standard systems and explore best practices, contributing to the green, low-carbon, and sustainable development of the global automotive industrial chain.
Yang Jun said, "Entering the carbon neutral era, smart takes a responsible stance on decarbonisation, implementing sustainable development measures through technological innovation and cooperating with excellent partners to promote coordinated decarbonisation across the industry and supply chain. Let's explore the best solutions for future low-carbon mobility together."
As a leading global technical service provider, TUV Rheinland has been providing green solutions for customers who are concerned about energy conservation, environmental protection, low carbon, and emission reduction since 2010. To date, it has provided services such as data collection for energy consumption and carbon emission as well as modeling quantitative indexing and evaluation for the entire life cycle for industries including automotive vehicles and components, chemicals, photovoltaics, electrical and electronics, real estate, batteries, and building materials, covering all aspects of raw materials, design and development, production processes, and product recycling.
In recent years, TUV Rheinland has successively launched related services such as energy management, energy saving diagnosis, life cycle assessment (LCA), product carbon footprint, water footprint, environmental product declaration (EPD), green factory, and supply chain energy saving diagnosis service, and dedicated itself to continuously improving its level of service capability in the field of low-carbon energy and sustainable development in order to contribute to the green and low-carbon transformation of enterprises and promote the high-quality development of industrial chains.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tuv-rheinland-and-smart-reach-strategic-cooperation-to-promote-low-carbon-transformation-and-sustainable-development-in-the-automotive-value-chain-301785909.html
SOURCE TUV Rheinland Greater China
The health facility to offer limited-edition digital content
TOKYO, Japan, March 30, 2023 /PRNewswire/ -- 5 Stars Medical Club, a luxury membership medical club that owns and operates the Clinic 9ru cosmetic dermatology and The Prevention Clinic Tokyo VIP health screen clinics, both located on the 4th floor of The Peninsula Tokyo, a five-star hotel, inked an agreement to sponsor Ayumi Hamazaki's commemorable ayumi hamasaki 25th Anniversary LIVE. As part of the sponsorship, the medical club will soon start offering limited-edition digital content. https://9ruprevention.com/en/
The Sponsorship
After her debut in 1998, Ayumi Hamasaki kept on going, building her career to this day without taking a moment to pause. In January of this year, she reached a new zenith with the release of her latest album Remember You, becoming the female artist with the greatest number of albums having entered the Top 10.
The medical club, on seeing how the renowned singer's way of life captivates many and how she continues to shine through the years, decided to enter into a sponsorship arrangement.
The medical club plans to start offering digital content prior to the ayumi hamasaki 25th Anniversary LIVE to be held on the 8th of April.
The Clinics
- 5 Stars Medical Club http://5stars.tokyo/
A luxury members-only medical club established in March 2021
5 Stars Medical Club is the owner and operator of CLINIC 9ru, a world-class cutting-edge anti-aging treatment and medical skin care facility, and THE PREVENTION CLINIC TOKYO, a next-generation health screening clinic that manages future risks by using state-of-the-art genetic testing technology. Both clinics are located on the 4th floor of The Peninsula Tokyo.
5 Stars Medical Club also participates in CARE, a Web3.0 medical data management project.
- THE PREVENTION CLINIC TOKYO https://preventionclinic.tokyo/
"Preventive health screening, a new approach to healthcare"
Rather than detecting an illness once it is already well underway, this method detects the signs and cause of any illness at an early stage and works to eliminate it by providing lifestyle guidance and cell therapy. By doing so, patients will be able to choose among novel preventive treatments such as immune-cell therapy or blood purification therapy without enduring major surgery or painful treatments that would force them to sacrifice their social lives.
The clinic is a luxury health screening facility with the most advanced equipment available today that makes services such as iPS cell banking possible.
- CLINIC 9ru https://9ru.tokyo/
"Treating the signs of aging in preparation for the future"
The clinic owns world-leading cutting-edge laser equipment for the treatment and care of aging skin. The state-of-the-art equipment has proven highly effective in treating dark spots, pores and dull skin, and in removing unwanted hair. A members-only facility offers cutting-edge regenerative medicine in luxurious private rooms.
Media Contacts CARE Project PR Office
Contact: Yamanouchi
email: info@wellnesscares.io
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/luxury-membership-5-stars-medical-club-signs-agreement-to-serve-as-sponsor-to-ayumi-hamasaki-25th-anniversary-live-301785907.html
SOURCE 5stars Medical Club
- Survey results reveal travel trends for 2023 including frequency of travel, timing of travel, and anticipated spending habits of travelers
INDIANAPOLIS, March 30, 2023 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning global insurance benefits and assistance services company, has released the results of its annual Travel Outlook Survey that surveyed IMG customers about their 2023 travel plans. The survey reveals 44% of respondents plan to travel internationally three or more times throughout the year, a 16% increase compared to 2022 survey results.
"It's clear that people's desire to travel, whether internationally or domestically, is not slowing down in 2023," said Steve Paraboschi, IMG President and CEO. "After the huge rebound in travel we saw in 2022, IMG is well-positioned for travel to continue to increase in 2023 with our market-leading products and customer service."
Travel Outlook Survey Findings:
Travelers are eager to travel sooner in 2023 than they were in 2022.
- 72% plan to take their next international trip before August 2023
- 41% increase compared to 2022 survey results
In 2023, travelers are preparing to spend more money than they typically have in the past.
- 35% plan to spend more on travel in 2023 than they did in 2022
International and/or emergency medical coverage continues to be the most important insurance benefit to travelers in 2023, while coverage for trip cancellation and travel delay is close behind.
- Top concerns travelers have while planning or taking a trip:
- Getting sick or having an accident while at their destination
- Needing to cancel their trip before departure
- Issues getting to or from their destination
- Needing to interrupt a trip while at their destination
"IMG has been a respected leader in the travel medical insurance market for dozens of years, but interest in our iTravelInsured plans, which provide trip cancellation, trip interruption, and travel delay benefits, has never been higher," said Paraboschi.
Many travelers plan to travel domestically in 2023, but a portion of travelers don't traditionally invest in travel insurance with trip cancellation and/or travel delay benefits for such trips.
- 89% plan to travel domestically in 2023
- 48% plan to travel domestically 3+ times in 2023
- Only 19% purchased travel insurance with trip cancellation and/or travel delay benefits for at least 1 domestic trip in 2022
"These results show that there is a great need for travelers to better understand the importance of travel insurance, even for their domestic trips," said Amanda Winkle, IMG Chief Operating Officer. "Travelers are planning to spend more on their trips this year and are concerned about the ability to cancel those trips, which is all the more reason why travelers need to be purchasing travel insurance to protect their investments."
The top 5 countries respondents plan to travel to next include:
- Mexico – top country 3 years in a row
- Canada
- Japan
- Italy
- Spain
To learn more about IMG's award-winning travel and health safety solutions, please visit www.imglobal.com.
About International Medical Group® (IMG®)
International Medical Group® (IMG®), a SiriusPoint company, is an award-winning global insurance benefits and assistance services company that has served millions of members worldwide since its founding in 1990. The preeminent provider of travel and health safety solutions, IMG offers a wide range of insurance programs, including international private medical insurance, travel medical insurance, and travel insurance, as well as enterprise services, including insurance administrative services and 24/7 emergency medical, security, and travel assistance. IMG's world-class services, combined with an extensive product portfolio, provide Global Peace of Mind® for travelers, students, missionaries, marine crews, and any other individuals or groups traveling, working, or living away from home. For more information, please visit www.imglobal.com.
SOURCE International Medical Group (IMG)
BASEL, Switzerland, March 30, 2023 /PRNewswire/ -- ACROBiosystems has begun to narrow its focus into helping accelerate the process between preclinical, clinical and commercialization. With over 10 years development, ACROBiosystems continues to surprise and bring new solutions to the pharmaceutical industry that assists in therapeutic manufacturing and its subsequent commercialization.
The establishment of a GMP quality management system, which upholds the strict standards throughout preclinical and clinical manufacturing, is no easy task. This substantial commitment is demonstrated by an investment in a GMP-grade production facility. ACROBiosystems' GMP facility with over 180,000 sq. ft available for manufacturing GMP products, including cytokines, enzymes, and antibodies. ACROBiosystems also offers custom GMP-grade raw material development starting from its targeted protein design, gene synthesis, vector construction, protein expression, and scale-up / scale-out production services.
Operated by its subsidiary, ACROBiosystems also emphasizes the importance to its clinical-focused strategy. ACRODiagnostics Inc. is a translational medicine biotechnology company in the ACROBiosystems group focused on providing analytical reagents and custom services for the clinical diagnostics industry. ACRODiagnostics has assembled a comprehensive pathology assay development team, including more than 10 years of experience in the diagnostic kit development and CRO services. The ClinMax™ product line includes both biological and clinical sample analytical kits, to help accelerate the clinical translation and commercialization of therapies. With a product development team rich in experience in designing, developing, and validating kits for various platforms, products offered are ensured to be low-risk and high-quality, ideal for clinical research.
"With our first strategic development phase success, we begin to enter the second phase our strategic development which is to focus on more clinically relevant applications and scale-up our manufacturing capabilities. This helps support a large-scale, high-quality, and more localized supply chain response to assist the needs of our clinical customers." reveals Mike Chen, Chairman and CEO of ACROBiosystems.
ACROBiosystems was founded on customer needs and continues to support preclinical, clinical, and commercialization efforts worldwide.
About ACROBiosystems Inc.
ACROBiosystems Group (SZ.301080) is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.
View original content:https://www.prnewswire.com/apac/news-releases/acrobiosystems-new-strategic-focus--streamlining-the-transition-from-preclinical-development-to-commercialization-301785890.html
SOURCE ACROBiosystems Group
